Novartis Ag

Ciba-geigy Corporation

Novartis Finance Corporation

Schering Aktiengesellschaft

Novartis Corporation

Novatis Ag

Other

Irm LLC

Guido Bold

Paul William Manley

Marc Lang

Pascal Furet

Hans-Georg Capraro

Peter Traxler

Alexander Fassler

Jeanette Marjorie Wood

Vito Guagnano

Andrea Vaupel

Karl-Heinz Altmann

Giorgio Caravatti

Satish Chandra Khanna

Shripad S Bhagwat

J&ouml;rg Frei

Rudolf Duthaler

Andreas Huth

Dieter Seidelmann

Karl-Heinz Thierauch

Andreas Menrad

Andreas Floersheimer

Stefano Ferrari

Martin Haberey

Jorg Frei

Peter Schneider

Bernhard Wietfeld

Simona Cotesta

Jürgen Mestan

Carole Pissot Soldermann

Richard Heng

Martin Krüger

David Raymond Stover

Helmut Mett

Francesco Hofmann

Jutta Blank

Janet Dawson King

Alexander F&auml;ssler

Janis Karlis Lazdins

Peter Herold

Hans Allgeier

Heinrich Rueeger

Robert W Lang

Konrad Oertle

Martin Riediker

Roland Heckendorn

John G Dingwall

Joseph Schoepfer

Antonio Togni

Christof Angst

Derek E Brundish

Graham E Fagg

Nathanael Schiander Gray

Yi Liu

Andreas Hafner

Eckhard Ottow

Werner Breitenstein

Tetsuo Uno

Clive McCarthy

Qiang Ding

Guobao Zhang

Bing Li

Keiichi Masuya

Taebo Sim

Carsten Spanka

Michael Schirner

Heinz Steiner

Peter Van Hoogevest

Vincent Bordas

Martin Kr&uuml;ger

Urs Regenass

Johannes Rosel

Frederic Cumin

Heinrich Rueger

Andreas Fl&ouml;rsheimer

Eugen Boss

Joerg Frei

Andreas Martin-Kohler

Urs Séquin

Jose Brüggen

Jörg Frei

J&uuml;rgen Mestan

Wolfgang Karl-Diether Brill

Clive Novartis Ag Mccarthy

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. 

Imidazopyrrolidine derivatives and their use in the treatment of disease

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (1) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. 

Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease

Pyrrolopyrrolone derivatives and their use as BET inhibitors

The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

Pyrirnidinyl aryl urea derivatives being FGF inhibitors

The invention relates to compounds of formula (I) wherein the substituents X, R, R, Rand Rhave the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.

Compounds and compositions as protein kinase inhibitors

Pyrimidinyl aryl urea derivatives being FGF inhibitors

The invention relates to novel compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumor diseases. 

Heterobicyclic carboxamides as inhibitors for kinases

The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases. 

The invention relates to new phthalazine derivatives of formula I, and to processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof alone or in combination with one or more other pharmaceutically active compounds for the treatment especially of a disease that responds to the inhibition of especially the vascular endothelial growth factor receptor kinase, preferably the treatment of a proliferative disease, or the treatment of inflammatory rheumatic or rheumatoid arthritis and/or pain; and the use of such a compound alone or in combination with one or more other pharmaceutically active compounds for the manufacture of a pharmaceutical preparation for the treatment of said diseases in an animal.

Phthalazine derivatives with angiogenesis inhibiting activity

The invention relates to compounds of the formula (I) wherein the moieties R1, R2, R3, R9, R10 and Q and X, Y and Z are as defined in the specification, and salts thereof, as well as their use, methods of use for them and method of their synthesis, and the like. The compounds are protein kinase inhibitors and can, inter alia, be used in the treatment of various proliferative diseases. 

Phenylacetamides suitable as protein kinase inhibitors

The invention relates to compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases. 

Bicyclic amides as kinase inhibitors

The invention relates to novel compounds of Formula I: wherein

Cyclic diaryl ureas suitable as tyrosine kinase inhibitors

The invention relates to thiazole and pyrazole derivatives of formula (I) wherein Q is S and X is C, or Q is CH and X is N; Ris unsubstituted or substituted phenyl; and Ris unsubstituted or substituted aryl or heteroaryl; or a salt of the said compounds, and to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumour disease, in particular such diseases which respond to an inhibition of the Flt-3 kinase. 

Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors

The invention relates to the use of diaryl urea derivatives in the treatment of protein kinase dependent diseases or for the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of diaryl urea derivatives in the treatment of said diseases, pharmaceutical preparations comprising diaryl urea derivatives for the treatment of said diseases, diaryl urea derivatives for use in the treatment of said diseases, novel diaryl urea derivatives, pharmaceutical preparations comprising these novel diaryl urea derivatives, processes for the manufacture of the novel diaryl urea derivatives, the use or methods of use of the novel diaryl urea derivatives as mentioned above, and/or these novel diaryl urea derivatives for use in the treatment of the animal or human body.

Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases

The invention relates to anthranilic acid amide derivatives of formula I, 

Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors

Growing community of inventors

Gipf-Oberfrick, Switzerland

Guido Bold